-
Product Insights
Biliary Tumor - Drugs In Development, 2024
Empower your strategies with our Biliary Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Bile duct cancer, or cholangiocarcinoma, is a rare malignancy arising from malignant cells forming in the bile ducts. It presents in two main types: intrahepatic, occurring inside the liver, and extrahepatic, forming outside the liver. Extrahepatic bile duct cancer further divides into perihilar, found where the right and left bile ducts meet, and distal, located where liver and gallbladder ducts merge. Symptoms...
-
Product Insights
Squamous Non-Small Cell Lung Carcinoma - Drugs In Development, 2024
Empower your strategies with our Squamous Non-Small Cell Lung Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Squamous cell carcinoma (SCC) of the lung, a subtype of non-small cell lung cancer (NSCLC), typically arises centrally in the main airways like the bronchi. This cancer variant is predominantly linked to tobacco smoke, being the primary cause of cellular transformation. Smoking accounts for about 80% of lung cancer cases in men and 90% in women, with SCC showing...
-
Product Insights
Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) - Drugs In Development, 2024
Empower your strategies with our Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) – Drugs In Development, 2024 report and make more profitable business decisions. Leptomeningeal carcinomatosis is a condition involving the infiltration of cancer into the protective layers of the brain, specifically the pia mater and arachnoid mater. Solid tumors, notably breast, lung, melanoma, gastrointestinal, and primary central nervous system tumors, can give rise to leptomeningeal carcinomatosis. Cancer cells may reach the leptomeninges through various routes, such as direct seeding from brain...
-
Product Insights
Malignant Fibrous Histiocytoma - Drugs In Development, 2024
Empower your strategies with our Malignant Fibrous Histiocytoma – Drugs In Development, 2024 report and make more profitable business decisions. Malignant fibrous histiocytoma, now termed undifferentiated pleomorphic sarcoma (UPS), is thought to originate from primitive mesenchymal cells, emerging in soft tissue or bone, typically in the extremities or retroperitoneum. Most common in late adulthood, it exhibits a slight male predominance, constituting the most prevalent soft tissue sarcoma. The subtypes include storiform/pleomorphic, myxoid, giant cell, inflammatory, and angiomatoid. Diagnostic imaging, such as...
-
Product Insights
Malignant Neoplasms - Drugs In Development, 2024
Empower your strategies with our Malignant Neoplasms – Drugs In Development, 2024 report and make more profitable business decisions. A tumor is a mass comprising atypical neoplastic cells, frequently exhibiting pleomorphism and the capability to invade surrounding tissues. Malignant neoplasms possess the characteristic of metastasizing to distant anatomical sites and may recur even after surgical excision. Among the most prevalent types of malignant neoplasms are carcinomas, which arise from epithelial tissues, Hodgkin and non-Hodgkin lymphomas originating in the lymphatic system, leukemias...
-
Product Insights
Oligodendroglioma - Drugs In Development, 2024
Empower your strategies with our Oligodendroglioma – Drugs In Development, 2024 report and make more profitable business decisions. Oligodendroglioma is a type of glioma (primary glial brain tumor). They often contain mineral deposits (called calcifications), areas of hemorrhage, and/or cysts. The most common symptoms are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy surgery and radiation therapy. The Oligodendroglioma drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
Papillary Renal Cell Carcinoma - Drugs In Development, 2024
Empower your strategies with our Papillary Renal Cell Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Papillary renal cell carcinoma (PRCC), a form of kidney cancer, originates in the tubes responsible for filtering waste from the blood. There are two subtypes: Type 1, more common and slow-growing, and type 2, aggressive and fast-growing. Symptoms may include blood in urine, pain, weight loss, fatigue, fever, or a palpable lump. Diagnosis involves imaging scans like CT, MRI, and...
-
Product Insights
Germ Cell Tumors - Drugs In Development, 2024
Empower your strategies with our Germ Cell Tumors – Drugs In Development, 2024 report and make more profitable business decisions. Germ cell tumors (GCTs), originating from primordial germ cells, exhibit diverse neoplasms primarily in gonads but also in the anterior mediastinum, pineal gland, and brain. Clinical classification distinguishes seminomas and non-seminomas, each with distinct prognoses. Seminomas typically show favorable outcomes, while non-seminomatous tumors may present with metastasis, including mixed germ cell components. Diagnosing germinoma involves imaging, serum/cerebrospinal fluid oncoprotein measurements, and...
-
Product Insights
Polycythemia Vera - Drugs In Development, 2024
Empower your strategies with our Polycythemia Vera – Drugs In Development, 2024 report and make more profitable business decisions. Polycythemia vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant, and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness, and excessive sweating. The risk of PV increases with age. Treatment includes alkylating agents. The Polycythemia Vera drugs in development market research report provide comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage...
-
Product Insights
Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) - Drugs In Development, 2024
Empower your strategies with our Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) – Drugs In Development, 2024 report and make more profitable business decisions. Primary myelofibrosis (PMF) is a rare bone marrow disorder marked by irregularities in blood cell production and the development of fibrous tissue within the bone marrow. Hematopoietic stem cells in the bone marrow, responsible for generating red blood cells, white blood cells, and platelets, undergo DNA changes in PMF, leading to continuous abnormal cell reproduction. Over time, these aberrant...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.